Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Relay Therapeutics, Inc. or Alkermes plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Relay Therapeutics, Inc. and Alkermes plc compare based on key financial metrics to determine which better meets your investment needs.

About Relay Therapeutics, Inc. and Alkermes plc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Latest Biotechnology and Relay Therapeutics, Inc., Alkermes plc Stock News

As of May 12, 2026, Relay Therapeutics, Inc. had a $2.5 billion market capitalization, compared to the Biotechnology median of $274.8 million. Relay Therapeutics, Inc.’s stock is up 51.5% in 2026, down 0.8% in the previous five trading days and up 331% in the past year.

Currently, Relay Therapeutics, Inc. does not have a price-earnings ratio. Relay Therapeutics, Inc.’s trailing 12-month revenue is $10.7 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -61.0%. Analysts expect adjusted earnings to reach $-1.707 per share for the current fiscal year. Relay Therapeutics, Inc. does not currently pay a dividend.

As of May 12, 2026, Alkermes plc had a $6.4 billion market cap, putting it in the 71st percentile of all stocks. Alkermes plc’s stock is up 37.5% in 2026, up 8.9% in the previous five trading days and up 27.08% in the past year.

Currently, Alkermes plc’s price-earnings ratio is 42.1. Alkermes plc’s trailing 12-month revenue is $1.6 billion with a 9.8% net profit margin. Year-over-year quarterly sales growth most recently was 28.2%. Analysts expect adjusted earnings to reach $1.433 per share for the current fiscal year. Alkermes plc does not currently pay a dividend.

How We Compare Relay Therapeutics, Inc. and Alkermes plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Relay Therapeutics, Inc. and Alkermes plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Relay Therapeutics, Inc. and Alkermes plc Growth Grades

Company	Ticker	Growth
Relay Therapeutics, Inc.	RLAY	F
Alkermes plc	ALKS	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Relay Therapeutics, Inc. has a Growth Score of 3, which is Very Weak. Alkermes plc has a Growth Score of 62, which is Strong.

The Growth Grade Winner: Alkermes plc

As you can clearly see from the Growth Grade breakdown above, Alkermes plc has a more attractive growth grade than Relay Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Alkermes plc could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Relay Therapeutics, Inc. and Alkermes plc’s Momentum Grades

Company	Ticker	Momentum
Relay Therapeutics, Inc.	RLAY	A
Alkermes plc	ALKS	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Relay Therapeutics, Inc. has a Momentum Score of 95, which is Very Strong. Alkermes plc has a Momentum Score of 63, which is Strong.

The Momentum Grade Winner: Relay Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Relay Therapeutics, Inc. is considered to have stronger momentum compared to Alkermes plc. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Relay Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Relay Therapeutics, Inc. and Alkermes plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Relay Therapeutics, Inc.	RLAY	D
Alkermes plc	ALKS	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Relay Therapeutics, Inc. has a Earnings Estimate Score of 29, which is Negative. Alkermes plc has a Earnings Estimate Score of 26, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Relay Therapeutics, Inc. or Alkermes plc has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Relay Therapeutics, Inc. or Alkermes plc is the better investment when it comes to estimate revisions.

Other Relay Therapeutics, Inc. and Alkermes plc Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Relay Therapeutics, Inc. and Alkermes plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Relay Therapeutics, Inc. or Alkermes plc Stock?

Overall, Relay Therapeutics, Inc. stock has a Growth Score of 3, Momentum Score of 95 and Estimate Revisions Score of 29.

Alkermes plc stock has a Growth Score of 62, Momentum Score of 63 and Estimate Revisions Score of 26.

Comparing Relay Therapeutics, Inc. and Alkermes plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.